Daytrana Methylphenidate Patches Recalled for Defective Delivery System
Noven Pharmaceuticals is recalling specific lots of Daytrana methylphenidate transdermal patches distributed nationwide because the delivery system is out of specification for shear. The affected lots require patient and healthcare provider attention.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard is a manufacturing defect in the delivery system specification, a product quality issue rather than a direct safety threat to patient health.
Plain-English summary
Noven Pharmaceuticals Inc is recalling specific lots of Daytrana (methylphenidate transdermal system) 10mg patches due to a defective delivery system that is out of specification for shear.
The affected lots are #91955 (expiration 7/2023) and #93039 (expiration 10/2023). Distribution was nationwide in the United States. Package NDC is 68968-5552-3.
Patients using Daytrana patches should verify the lot number on their medication carton. Those with patches from the affected lots should contact their healthcare provider or pharmacist for guidance on next steps.
The recalled product
- Product
- DAYTRANA (METHYLPHENIDATE)
- Brand
- DAYTRANA
- Manufacturer
- Noven Pharmaceuticals Inc
- Hazard
- drug-delivery-failure
- adhesion-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot#: 91955
- Exp. 7/2023
- 93039
- Exp. 10/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DAYTRANA
- HighDaytrana methylphenidate patches recalled for defective delivery system
FDA (Drugs) · 2023-03-29
- HighDaytrana Methylphenidate Transdermal Patches Recalled for Defective Delivery System
FDA (Drugs) · 2023-03-29
- HighDaytrana Methylphenidate Patches Recalled for Defective Transdermal Delivery System
FDA (Drugs) · 2023-03-29
- HighDaytrana transdermal methylphenidate patches recalled for adhesive defect
FDA (Drugs) · 2022-12-07
- HighMethylphenidate Patch Recall: Defective Delivery System and Adhesive Issues
FDA (Drugs) · 2022-07-06
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27